Reported 16 days ago
Eli Lilly, known for its anticipated growth in the GLP-1 medication market for diabetes and obesity, is being compared to Nvidia's rise amid the AI boom. With successful products like Mounjaro and Zepbound, and innovative approaches in Alzheimer's treatments and partnerships with AI, Lilly is poised for significant long-term growth. The company's diverse portfolio and ongoing developments suggest that now could be a prime time for investors to consider Eli Lilly as a generational investment opportunity.
Source: YAHOO